연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
465. ERK1/2 is an endogenous negative regulator of the γ-secretase activity.
Kim S-K, Park H-J, Hong HS, Baik EJ, Jung MW, Mook-Jung I.
FASEB J 2006; 20:157-159.
Link
464. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Han, W. Han, M. R. Kang, J. J. Bae, J. Y. Lee, J. H. Bae, Y. J. Lee, J. E. Shin, H. J. Hwang, K. T. Hwang, S. E. Kim, S. W. Noh, D. Y.
BMC Cancer 2006; 6: 92
Link
463. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells.
Kim, H. K.De La Luz Sierra, M. Williams, C. K. Gulino, A. V. Tosato, G.
Blood 2006. 108: 812-820.
Link
462. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, Kim TY, Kim YW, Bang YJ, Heo DS.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4232-6.
Link
461. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
Lee KW, Yun T, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK.
Leuk Lymphoma. 2006 Jul;47(7):1274-82.
Link
460. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Lee KH, Han SW, Hwang PG, Oh DY, Kim DW, Chung DH, Im SA, Kim TY, Heo DS, Bang YJ.
Jpn J Clin Oncol. 2006 Jun;36(6):344-50.
Link
459. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ.
Clin Cancer Res. 2006 Apr 15;12(8):2538-44.
Link
458. Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. J Korean Med Sci.
Park SR, Baek JY, Kim DW, Im SA, Kim TY, Bang YJ, Kim NK, Jeon YK, Kim CW, Heo DS.
2006 Aug;21(4):633-8.
Link
457. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther.
Lee JH, Park JH, Jung Y, Kim JH, Jong HS, Kim TY, Bang YJ.
2006 Dec;5(12):3085-95.
Link
456. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Han, S. W. Kim, T. Y. Lee, K. H. Hwang, P. G. Jeon, Y. K. Oh, D. Y. Lee, S. H. Kim, D. W. Im, S. A. Chung, D. H. Heo, D. S. Bang, Y. J.
Lung Cancer 2006; 54:201-207.
Link